Stem cell therapy available at Jipmer

May 07, 2015 12:00 am | Updated 05:52 am IST - PUDUCHERRY:

Stem cell therapy will now be made available to patients at JIPMER, following the inauguration of the Immunotherapy unit of the Department of Clinical Immunology on Wednesday by Dr. Subhash Chandra Parija, director of the institute. The facility will treat patients with autoimmune and immunological disorders through stem cell therapy, said a press release.

Dr. Parija said that Immunotherapy in the form of stem cell therapy can play an important role in the management of long term disease control of autoimmune disorders, and in some cases even cure.

Joint PhD programme with France

Dr. Philippe ARHETS, Counselor for Science and Technology from the French embassy in India, New Delhi, supervised the conduct of PhD examination for the first Cotutelle / joint PhD programme between JIPMER and Hospital Saint Louis, University of Paris 7. He is visiting JIPMER to foster and strengthen scientific collaborations between JIPMER and French Hospitals and research institutions, said the release.

New pharmacy counters

Aimed at reducing the waiting time, special pharmacy counters were inaugurated in the Super Specialty Block on Tuesday. A press release said that more than 50 per cent of the 8000 patients per day in the out-patient departments (OPDs) visit the OPDs of the Super Specialty Block. The new counters will cater especially to the vulnerable patients, while ensuring the rapid dispensing of medicines. It will have comfortable seating facility.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.